EGFR and breast neoplasm: Furthermore, while a number of in vivo studies have demonstrated the enhanced efficacy of external beam radiotherapy when given in combination with PARPi27,50, the only reported study combining a PARPi with radionuclide therapy showed that a 177Lu-labelled anti-EGFR antibody given in combination with rucaparib was more effective against a breast tumour model than either agent alone30.